



US009364515B2

(12) **United States Patent**
Cincotta

(10) **Patent No.:** **US 9,364,515 B2**
(45) **Date of Patent:** **Jun. 14, 2016**

(54) **THERAPEUTIC PROCESS FOR THE TREATMENT OF THE METABOLIC SYNDROME AND ASSOCIATED METABOLIC DISORDERS**

(71) Applicant: **VeroScience LLC**, Tiverton, RI (US)

(72) Inventor: **Anthony H. Cincotta**, Tiverton, RI (US)

(73) Assignee: **VeroScience LLC**, Tiverton, RI (US)

(*) Notice: Subject to any disclaimer, the term of this patent is extended or adjusted under 35 U.S.C. 154(b) by 0 days.

(21) Appl. No.: **14/447,247**

(22) Filed: **Jul. 30, 2014**

(65) **Prior Publication Data**

US 2014/0342975 A1 Nov. 20, 2014

Related U.S. Application Data

(60) Division of application No. 13/200,127, filed on Sep. 19, 2011, now Pat. No. 8,821,915, which is a continuation-in-part of application No. 10/944,617, filed on Sep. 17, 2004, now Pat. No. 8,021,681, which is a continuation-in-part of application No. 10/635,841, filed on Aug. 6, 2003, now abandoned.

(60) Provisional application No. 60/402,231, filed on Aug. 9, 2002.

(51) **Int. Cl.**

A23L 1/30 (2006.01)
A61K 38/16 (2006.01)
A23L 1/29 (2006.01)
A61K 31/198 (2006.01)
A61K 31/20 (2006.01)
A61K 31/201 (2006.01)
A61K 31/202 (2006.01)
A61K 31/405 (2006.01)
A61K 31/70 (2006.01)
A23L 1/304 (2006.01)
A23L 1/0522 (2006.01)
A23L 1/09 (2006.01)

(52) **U.S. Cl.**

CPC *A61K 38/16* (2013.01); *A23L 1/293* (2013.01); *A23L 1/296* (2013.01); *A61K 31/198* (2013.01); *A61K 31/20* (2013.01); *A61K 31/201* (2013.01); *A61K 31/202* (2013.01); *A61K 31/405* (2013.01); *A61K 31/70* (2013.01); *A23L 1/0522* (2013.01); *A23L 1/09* (2013.01); *A23L 1/304* (2013.01); *A23V 2002/00* (2013.01)

(58) **Field of Classification Search**

CPC *A23L 1/304*; *A23L 1/0522*; *A23L 1/09*
USPC 426/72, 2, 74
See application file for complete search history.

(56) **References Cited**

U.S. PATENT DOCUMENTS

4,009,265 A 2/1977 Howard
4,338,304 A 7/1982 Kimimae et al.
4,446,138 A 5/1984 Pack
4,659,715 A 4/1987 Meier et al.
4,749,709 A 6/1988 MeJer et al.
4,783,369 A 11/1988 Sugata et al.
4,783,469 A 11/1988 Meier et al.
4,791,125 A 12/1988 Clark
4,971,969 A 11/1990 Carlier et al.
5,006,526 A 4/1991 Meier et al.
5,066,495 A 11/1991 Moro et al.
5,344,832 A 9/1994 Cincotta et al.
5,468,755 A 11/1995 Cincotta et al.
5,496,803 A 3/1996 Meier et al.
5,554,623 A 9/1996 Cincotta et al.
5,565,454 A 10/1996 Cincotta
5,585,347 A 12/1996 Meier et al.
5,614,492 A 3/1997 Habener
5,626,860 A 5/1997 Cincotta et al.
5,635,512 A 6/1997 Cincotta et al.
5,654,313 A 8/1997 Cincotta et al.
5,668,155 A 9/1997 Cincotta et al.
5,679,685 A 10/1997 Cincotta et al.
5,688,794 A 11/1997 Meier et al.
5,696,128 A 12/1997 Cincotta et al.

(Continued)

FOREIGN PATENT DOCUMENTS

CN 1678313 10/2005
CN 1950078 4/2007

(Continued)

OTHER PUBLICATIONS

Aellig et al., "Comparative pharmacokinetic investigations with tritium-labeled ergot alkaloids after oral and intravenous administration in man," *Int J Clin Pharmacol*, 1997, vol. 15, pp. 106-112.

Alford et al., "The effects of variations in carbohydrate, protein, and fat content of the diet upon weight loss, blood values, and nutrient intake of adult obese women," *Journal of the American Dietetic Association*, Apr. 1990, 90(4):435-540.

Ansel et al., *Pharmaceutical Dosage Forms and Drug Delivery Systems*, 1995, pp. 78-81.

Armentero et al., "Dopamine Receptor Agonists Media neuroprotection in malonate-Induced striatal lesion in the Rat," *Experimental Neurology*, Dec. 2002, 178(2):301-305.

(Continued)

Primary Examiner — Kevin E Weddington

(74) *Attorney, Agent, or Firm* — Fish & Richardson P.C.

(57) **ABSTRACT**

The present invention is directed to a method of treating a patient suffering from the metabolic syndrome and/or related disorders including obesity, Type 2 diabetes, pre-diabetes, hypertension, dyslipidemia, insulin resistance, endothelial dysfunction, pro-inflammatory state, and pro-coagulative state, and comprising the steps of (a) providing to the patient a dietary regimen that decreases overactive CNS noradrenergic tone; followed by (b) providing to the patient a dietary regimen that increases dopaminergic tone while maintaining the above decreased overactive CNS noradrenergic tone. The present invention is also directed to food products useful in implementing the dietary regimens.

12 Claims, No Drawings